

DOI: 10.21767/2572-5548.100040

2020 Market Analysis of Chronic Obstructive Pulmonary Disease Conference

Xiaohong Zhou

Principal Scientist, Astra Zeneca, Gothenburg, Sweden

***Corresponding author:** Xiaohong Zhou Principal Scientist, Astra Zeneca, Gothenburg, Sweden; E-mail: Xiaohong.Zhou@astrazeneca.com

Rec date: Jul 05, 2020; **Acc date:** Jul 19, 2020; **Pub date:** Jul 27, 2020

Copyright: © 2020 Zhou X, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Zhou X, et al. (2020) 2020 Market Analysis of Chronic Obstructive Pulmonary Disease Conference. *Chron Obstruct Pulmon Dis* 5.2

Market Analysis

Increasing prevalence of respiratory diseases owing to the growing aging population and increasing pathogens in the environment has been the key factor driving the Chronic Obstructive Pulmonary Disease (COPD) market globally. Pharmaceutical companies have been developing new bio-based medications in combination with bio-technology which promises immense growth opportunities along with sustainable development for COPD market over the next decade.

The global COPD drug market is a multi-billion dollar market which has a history of several decades and has witnessed number of technological advancements and product development over the past few years. Upcoming treatment methodologies such as once-a-day combination products and monoclonal antibodies have created new opportunities for the market growth. The global market for Chronic Obstructive Pulmonary Disease (COPD) prescription drugs was valued at \$34.9 billion in 2011. This figure is expected to reach \$38 billion in 2012 and \$47.1 billion in 2018, growing at a five-year compound annual growth rate (CAGR) of 4.4%. The global COPD market is estimated to currently be worth \$11.3 billion and is forecast to reach a value of \$15.6 billion by 2020. Currently, North America leads the global market for COPD drugs and devices. However, North America and Europe is expected to lose out some of the market share to other emerging regional markets owing to the expiry of several patents of pharmaceutical companies operating in these regions. Asia Pacific is estimated to be the rapid regional market for COPD due to the increased incidence of respiratory diseases in industrial regions. A large decrease in COPD mortality rates COPD deaths fell only slightly, from 3 million in 1990 to 2.8 million in 2010 because the mean age of the population increased. The number of COPD

deaths in 2010 would have risen to 5.2 billion if the age specific mortality rates had remained constant.

Changes in smoking led to only a small increase in age specific mortality rates. Global outlines of mortality are changing, mainly due to three related transformations: an epidemiological transition driven by change in global risks, with falling death rates in childhood associated with infectious disease, a demographic transition with more people surviving into later life, and a health care transition with improved efficacy of both preventive and curative or palliative treatments.




Figure 1: Regional scope of COPD




Figure 2: Members Associated with COPD

DOI: 10.21767/2572-5548.100040

Importance & Scope

Chronic obstructive pulmonary disease (COPD) is the fourth leading causes of death in the world. Moreover, among the top five causes of death, this disease is the only one with increasing mortality rates. COPD is an essential public health problem in many countries which is evaluated to become the fifth reason for disability. COPD is a common condition that mainly affects aged or adults who smoke. The condition cannot be cured or reversed, but for many people treatment can help them to keep it under control so it does not affect their daily activities. COPD Conference 2020 is to understand the depth of the disease and proceed for the future research.

The COPD Conference 2020 will discover the new concepts and informative session program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We delightedly invite you to join us at the

COPD Conference 2020, where you will have essential experience with scholars from around the world. All members from COPD Conference 2020 organizing committee lookforward to meet you in London, UK.

Associations:

In London

Society of Pulmonology and Thoracic Surgery
 The World Association for Bronchology and Interventional Pulmonology

In Europe

European Respiratory Society
 European Federation of Allergy and Airways Diseases Patient Associations
 European Idiopathic Pulmonary Fibrosis & Related Disorders Federation
 European Pulmonary Hypertension Association
 European Association for Bronchology and Interventional Pulmonology
 Cystic Fibrosis Europe
 British Lung Foundation

British Thoracic Society
 Association for Respiratory Technology and Physiology
 The Primary Care Respiratory Society UK
 European COPD Coalition European Lung Foundation

In Worldwide

Algerian Society of Pneumology
 Association Argentina de Medicina Respiratoria
 Thoracic Society of Australia and New Zealand
 Austrian Society for Pneumology
 Belgian Thoracic Society
 Sociedade Brasileira de Pneumologia e Tisiologia
 Bulgarian Respiratory Society
 Canadian Thoracic Society Chinese Thoracic Society
 Croation Respiratory Society
 Egyptian Pediatric Pneumology Society
 Forum of International Respiratory Societies Russian Respiratory Society
 Peruvian Society of Pneumology German Center for Lung Research




Figure 3: Universities Associated with COPD